NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial (vol 391, pg 1174, 2018)

被引：0
|
作者：
Harrison, S. A.
Rinella, M. E.
Abdelmalek, M. F.
机构：
来源：
LANCET | 2018年 / 391卷 / 10126期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E16 / E16
页数：1
相关论文
共 50 条
  • [21] A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL OF EMRICASAN IN SUBJECTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND FIBROSIS
    Harrison, Stephen A.
    Goodman, Zachary D.
    Jabbar, Abdul
    Younes, Ziad
    Vemulapalli, Ravi
    Freilich, Bradley L.
    Sheikh, Muhammad Y.
    Schattenberg, Joern
    Kayali, Zeid
    Zivony, Adam Seth
    Sheikh, Aasim M.
    Garcia-Samaniego, Javier
    Satapathy, Sanjaya Kumar
    Therapondos, George
    Mena, Edward A.
    Schuppan, Detlef
    Robinson, James M.
    Chan, Jean Lin
    Hagerty, David
    Sanyal, Arun J.
    HEPATOLOGY, 2019, 70 : 43A - 44A
  • [22] Semaglutide in patients with non-alcoholic steatohepatitis: subgroup analysis of a randomised, placebo-controlled phase 2 trial
    Francque, Sven
    Kjaer, Mette
    Ladelund, Steen
    Okanoue, Takeshi
    Mateva, Lyudmila
    Shrestha, Ichhya
    Harrison, Stephen
    JOURNAL OF HEPATOLOGY, 2021, 75 : S609 - S610
  • [23] Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial
    Loomba, Rohit
    Morgan, Erin
    Watts, Lynnetta
    Xia, Shuting
    Hannan, Lisa A.
    Geary, Richard S.
    Baker, Brenda F.
    Bhanot, Sanjay
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2020, 5 (09): : 829 - 838
  • [24] Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo- controlled, phase 2b trial
    Harrison, Stephen A.
    Frias, Juan P.
    Neff, Guy
    Abrams, Gary A.
    Lucas, K. Jean
    Sanchez, William
    Gogia, Sudhanshu
    Sheikh, Muhammed Y.
    Behling, Cynthia
    Bedossa, Pierre
    Shao, Lan
    Chan, Doreen
    Fong, Erica
    de Temple, Brittany
    Shringarpure, Reshma
    Tillman, Erik J.
    Rolph, Timothy
    Cheng, Andrew
    Yale, Kitty
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (12): : 1080 - 1093
  • [25] Silymarin in non-cirrhotics with non-alcoholic steatohepatitis: A randomized, double-blind, placebo controlled trial
    Navarro, Victor J.
    Belle, Steven H.
    D'Amato, Massimo
    Adfhal, Nezam
    Brunt, Elizabeth M.
    Fried, Michael W.
    Reddy, K. Rajender
    Wahed, Abdus S.
    Harrison, Stephen
    PLOS ONE, 2019, 14 (09):
  • [26] Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial
    Traussnigg, Stefan
    Schattenberg, Jorn M.
    Demir, Munevver
    Wiegand, Johannes
    Geier, Andreas
    Teuber, Gerfinde
    Hofmann, Wolf Peter
    Kremer, Andreas E.
    Spreda, Frank
    Kluwe, Johannes
    Petersen, Jorg
    Boettler, Tobias
    Rainer, Florian
    Halilbasic, Emina
    Greinwald, Roland
    Prols, Markus
    Manns, Michael P.
    Fickert, Peter
    Trauner, Michael
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (10): : 781 - 793
  • [27] Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial (vol 392, pg 222, 2018)
    Wallace, D. J.
    Furie, R. A.
    Tanaka, Y.
    LANCET, 2018, 392 (10146): : 476 - 476
  • [28] Randomised Double-Blind Placebo-Controlled Trial of Inulin with Metronidazole in Non-Alcoholic Fatty Liver Disease (NAFLD)
    Chong, Clara Yieh Lin
    Orr, David
    Plank, Lindsay D.
    Vatanen, Tommi
    O'Sullivan, Justin M.
    Murphy, Rinki
    NUTRIENTS, 2020, 12 (04)
  • [29] The leukotriene receptor antagonist montelukast in the treatment of non-alcoholic steatohepatitis: A proof-of-concept, randomized, double-blind, placebo-controlled trial
    Abdallah, Mahmoud Samy
    Eldeen, Ahmed Hossam
    Tantawy, Sally Said
    Mostafa, Tarek Mohamed
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 906
  • [30] Effect of NGM282, an FGF19 Analogue, on Pruritus in Patients with Primary Sclerosing Cholangitis: Analysis of a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
    Mayo, Marlyn J.
    Ling, Lei
    Hudgens, Stacie
    Kim, Kathline H.
    Hirschfield, Gideon
    DePaoli, Alex
    Beuers, Ulrich
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E151 - E151
12345